Early investigational drugs targeting PPAR-α for the treatment of metabolic disease

Zhong Min Liu, Miao Hu, Paul Chan, Brian Tomlinson

研究成果: 雜誌貢獻文章同行評審

37 引文 斯高帕斯(Scopus)

摘要

Introduction: The fibrates have been used for many years to treat dyslipidemias and have also recently been shown to have anti-inflammatory effects. They are relatively weak PPAR-α agonists and do have some adverse effects. Novel compounds are in development, which are selective PPAR modulators (SPPARMs) and have more potent PPAR-α agonist activity. These may prove to have advantages in the treatment of dyslipidemia, insulin resistance and non-alcoholic fatty liver disease (NAFLD).Areas covered: This review focuses on PPAR-α agonists or SPPARMs in development describing the preclinical and early clinical studies. The information was obtained by searching the published literature and abstracts from recent meetings. Ongoing clinical trials were identified using the Clinicaltrial.gov database.Expert opinion: There is still a need for new drugs to treat atherogenic dyslipidemia. The highly potent and selective PPAR-α agonist K-877 has shown beneficial effects on atherogenic dyslipidemia and absence of some adverse effects seen with fibrates. The dual PPAR-α/PPAR-δ agonist GFT-505 has shown favorable results in improving atherogenic dyslipidemia and insulin resistance and appears to be a potential candidate for the treatment of NAFLD. Long-term trials are needed to assess the safety and efficacy of these new agents for cardiovascular and liver outcomes.
原文英語
頁(從 - 到)611-621
頁數11
期刊Expert Opinion on Investigational Drugs
24
發行號5
DOIs
出版狀態已發佈 - 五月 1 2015

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

指紋 深入研究「Early investigational drugs targeting PPAR-α for the treatment of metabolic disease」主題。共同形成了獨特的指紋。

引用此